Panacea Biotec

453.95
+17.60
(4.03%)
Market Cap
2,780.48 Cr
EPS
-0.19
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
490.55
52 Week Low
112.35
PB Ratio
3.21
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,687.75
#1 4,04,947.76
33.61
#1 49,887.20
12.06
#1 9,648
13.77
42.22
5,558.95
1,47,572.66
69.15
8,184.00
0.89
1,600
#1 64.53
39.57
1,459.45
1,17,867.36
22.92
26,520.70
14.17
4,155
47.38
43.18
3,131.65
1,05,989.27
56.83
10,785.70
11.59
1,656
13.54
45.06
2,338.15
96,467.05
46.77
10,615.60
19.57
1,942
-16.38
45.01
1,119.70
93,433.97
#1 17.01
28,905.40
12.36
5,578
1.69
35.86
1,972.95
90,073.25
30.58
20,141.50
#1 19.94
1,936
38.82
42.04
868.55
87,396.45
18.74
19,831.50
13.82
3,831
29.92
36.96
1,086.15
63,083.77
17.41
29,559.20
17.55
3,169
-10.04
36.48
29,577.50
62,850.12
46.40
6,097.20
10.80
1,201
16.01
43.00
Growth Rate
Revenue Growth
14.35 %
Net Income Growth
-95.55 %
Cash Flow Change
99.98 %
ROE
-95.52 %
ROCE
-70.49 %
EBITDA Margin (Avg.)
-110.83 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
123
122
114
485
131
129
171
144
134
184
144
173
136
234
158
1,821
151
143
157
163
163
149
159
150
122
155
170
Expenses
116
179
87
258
104
149
132
150
111
144
127
167
134
226
144
171
191
109
124
135
140
147
151
143
130
140
156
EBITDA
7
-57
27
228
27
-20
39
-6
23
40
17
6
2
8
14
1,650
-40
34
33
29
24
2
8
8
-8
14
14
Operating Profit %
-17 %
-48 %
21 %
-110 %
17 %
-19 %
21 %
-19 %
16 %
21 %
11 %
1 %
-1 %
3 %
8 %
-21 %
-72 %
-4 %
-8 %
-4 %
-8 %
-2 %
-0 %
-4 %
-12 %
5 %
5 %
Depreciation
14
14
52
13
11
11
11
10
11
11
11
12
11
11
11
11
10
10
10
10
10
9
9
9
9
9
9
Interest
25
29
-14
26
41
42
47
45
45
48
46
47
48
50
52
31
1
1
1
1
1
1
1
1
1
1
1
Profit Before Tax
-33
-99
-11
189
-25
-73
-19
-61
-34
-19
-40
-53
-57
-53
-49
1,608
-51
23
22
18
13
-8
-2
-2
-17
5
4
Tax
3
-2
5
3
3
2
2
9
0
0
0
2
0
0
0
371
5
8
3
31
2
1
1
-0
-1
0
-0
Net Profit
-35
-97
-16
186
-28
-75
-21
-70
-34
-19
-40
-54
-57
-53
-49
1,238
-56
16
19
-13
11
-8
-2
-2
-16
5
4
EPS in ₹
-5.75
-15.83
-2.60
30.35
-4.62
-12.25
-3.48
-11.38
-5.58
-3.16
-6.54
-8.84
-9.36
-8.65
-8.03
202.03
-9.17
2.56
3.16
-2.03
1.79
-1.35
-0.37
-0.23
-2.59
0.77
0.74

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,931
1,854
1,800
1,608
1,376
1,390
1,178
1,759
1,271
1,241
Fixed Assets
1,144
1,071
1,001
949
806
657
609
622
600
582
Current Assets
526
549
533
560
508
683
511
951
562
485
Capital Work in Progress
156
161
30
40
23
24
34
17
42
102
Investments
5
4
7
7
5
6
0
5
14
40
Other Assets
626
619
761
611
542
703
534
1,115
615
517
Total Liabilities
1,931
1,854
1,800
1,608
1,376
1,390
1,178
1,759
1,271
1,241
Current Liabilities
706
475
588
691
938
452
449
776
330
309
Non Current Liabilities
750
930
846
611
90
743
960
109
101
94
Total Equity
475
450
366
306
347
196
-232
874
840
838
Reserve & Surplus
449
426
340
293
335
139
-257
849
816
814
Share Capital
22
22
6
6
6
6
6
6
6
6

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-1
-10
-2
9
-2
26
12
-2
-11
7
Investing Activities
-37
17
-26
55
-6
-35
-48
1,283
430
10
Operating Activities
37
91
131
118
105
-31
107
-108
-423
-0
Financing Activities
-1
-117
-107
-164
-101
91
-47
-1,176
-18
-3

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.59 %
73.46 %
72.87 %
72.49 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.27 %
0.27 %
0.37 %
0.38 %
DIIs
1.27 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.29 %
0.43 %
0.43 %
0.54 %
0.00 %
0.00 %
0.84 %
1.07 %
1.16 %
1.17 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
17.34 %
15.21 %
15.57 %
15.99 %
15.14 %
15.60 %
15.79 %
15.97 %
15.82 %
16.15 %
19.20 %
19.63 %
19.90 %
20.42 %
18.11 %
18.98 %
Others
7.80 %
11.20 %
10.84 %
10.42 %
11.27 %
10.81 %
10.33 %
10.02 %
10.16 %
9.73 %
7.21 %
6.78 %
5.40 %
4.79 %
7.49 %
6.99 %
No of Share Holders
27,228
54,313
52,816
52,465
49,563
49,896
49,078
50,533
48,634
47,815
48,878
47,091
46,242
45,513
39,982
35,446

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Details Of Shares Dematerialized During March 20253 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20187 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20187 days ago
Announcement under Regulation 30 (LODR)-Change in Management10 days ago
Announcement under Regulation 30 (LODR)-Change in Management10 days ago
Announcement under Regulation 30 (LODR)-Change in Directorate10 days ago
Announcement under Regulation 30 (LODR)-Change in Directorate10 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report10 days ago
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot10 days ago
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 30, 2025
Closure of Trading WindowMar 26, 2025
Clarification On Movement In PriceMar 12, 2025
Clarification sought from Panacea Biotec LtdMar 11, 2025
Demat Report For The Month Of February 2025Mar 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 28, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 15, 2025
Integrated Filing (Financial)Feb 14, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 14, 2025
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31 2024Feb 14, 2025
Board Meeting Outcome for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2024 2. Appointment / Re-Appointment Of Directors 3. Change In Senior Management Personnel 4. ReFeb 14, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 13, 2025
Demat Report For The Month Of January 2025Feb 07, 2025
Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended December 31 2024Jan 31, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations)Jan 23, 2025
Details Of Shares Dematerialized During December 2024Jan 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Intimation Regarding Launch Of Baby Diapers And Wipes By CompanyS Wholly-Owned Subsidiary Panacea Biotec Pharma LimitedJan 03, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportDec 28, 2024
Intimation Of Further Investment In Panacea Biotec Inc. Made By The CompanyS Material Subsidiary Panacea Biotec Pharma LimitedDec 28, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementDec 09, 2024
Details Of Shares Dematerialized During November 2024Dec 06, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 27, 2024
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 26, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateNov 13, 2024
Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2024Nov 13, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On November 13, 2024Nov 13, 2024
Intimation Regarding:(A) Appointment Of Independent Director In The Company'S Unlisted Material Subsidiary Company Viz. Panacea Biotec Pharma Limited; And(B) Corporate Guarantee Proposed To Be Given By PBPL For Proposed Fund Raising By Panacea Biotec Limited By Way Of External Commercial BorrowingsNov 12, 2024
Details Of Share Dematerialised For The Month Of October, 2024Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018Nov 08, 2024
Update on board meetingNov 08, 2024
Board Meeting Intimation for Approving Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And HalfYear Ended September 30, 2024Oct 30, 2024
Announcement under Regulation 30 (LODR)-DemiseOct 16, 2024
Intimation Under Regulation 30 Read With 31A Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Regarding Submission Of Application For Reclassification From 'Promoters & Promoters' Group' Category To 'Public' Category Of Panacea Biotec LimitedOct 16, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 14, 2024
Details Of Share Dematerialised For The Month Of September, 2024 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018Oct 07, 2024

Technical Indicators

RSI(14)
Neutral
56.33
ATR(14)
Less Volatile
24.25
STOCH(9,6)
Neutral
51.36
STOCH RSI(14)
Oversold
1.50
MACD(12,26)
Bearish
-1.69
ADX(14)
Strong Trend
34.43
UO(9)
Bearish
51.08
ROC(12)
Downtrend And Accelerating
-2.55
WillR(14)
Neutral
-73.63